Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) FCF Margin (2016 - 2025)

Historic FCF Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 6127.12%.

  • Celldex Therapeutics' FCF Margin fell 49421400.0% to 6127.12% in Q2 2025 from the same period last year, while for Sep 2025 it was 6988.15%, marking a year-over-year decrease of 53876700.0%. This contributed to the annual value of 2275.2% for FY2024, which is 6900000.0% down from last year.
  • As of Q2 2025, Celldex Therapeutics' FCF Margin stood at 6127.12%, which was down 49421400.0% from 7865.47% recorded in Q1 2025.
  • In the past 5 years, Celldex Therapeutics' FCF Margin ranged from a high of 346.93% in Q2 2021 and a low of 26270.51% during Q1 2024
  • Its 5-year average for FCF Margin is 6574.54%, with a median of 3734.54% in 2021.
  • As far as peak fluctuations go, Celldex Therapeutics' FCF Margin plummeted by -232556200bps in 2024, and later surged by 184050500bps in 2025.
  • Quarter analysis of 5 years shows Celldex Therapeutics' FCF Margin stood at 4454.19% in 2021, then skyrocketed by 69bps to 1363.73% in 2022, then surged by 41bps to 803.66% in 2023, then crashed by -252bps to 2830.13% in 2024, then plummeted by -116bps to 6127.12% in 2025.
  • Its last three reported values are 6127.12% in Q2 2025, 7865.47% for Q1 2025, and 2830.13% during Q4 2024.